Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TAK-227 (ZED1227) is a potential first-in-class therapy designed to prevent the immune response to gluten in celiac disease, a serious autoimmune disease where the ingestion of gluten leads to inflammation and damage to the small intestine.
Lead Product(s): TAK-227
Therapeutic Area: Gastroenterology Product Name: ZED1227
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 20, 2022